Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study.

ABSTRACT:

Background

Patients with coronavirus disease 2019 (COVID-19) exhibit high thrombotic risk. The evidence on a potential independent prognostic role of antiplatelet treatment in those patients is limited. The aim of the study was to evaluate the prognostic impact of pre-admission low-dose acetylsalicylic acid (ASA) in a wide series of hospitalized patients with COVID-19.

Methods

This cohort study included 984 COVID-19 patients stratified according to ASA intake before hospitalization: ASA⁺ (n = 253) and ASA^- (n = 731). Patients were included in ASA⁺ group if they received it daily in the 7 days before admission. 213 (83%) were on ASA 100 mg daily. Primary endpoint was a composite of in-hospital death and/or need for respiratory support upgrade,

SUBMITTER: Sisinni A 

PROVIDER: S-EPMC8489263 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature